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bstract
A role of ACE I/D polymorphism in the pathogenesis of abdominal aortic aneurysm (AAA) has been demonstrated, possibly due to the
ffect of angiotensin II on vascular tissue remodelling. Angiotensin II exerts profibrogenic effects through the local induction of TGF-.
ysregulated TGF- signalling may result from mutations in TGFBR1 and TGFBR2 genes, thus resulting in degenerative changes in the
essel wall. We performed a case-control study in order to investigate the role of TGFBR1 9A6A polymorphism as predisposing factor to AAA
er se, and in the presence of ACE DD and AT1R 1166 CC genotypes in 201 AAA patients (mean age ± S.D., 71.5 ± 6.9) referred to the Unit of
ascular Surgery of the University of Florence, compared with 252 healthy controls (mean age ± S.D., 70.6 ± 8.6). A significant difference in
enotype distribution and allele frequency between patients and controls was found for ACE, but not for AT1R and TGFBR1 polymorphisms.
t univariate analysis a significant association between ACE DD, but not AT1R CC and TGFBR1 6A allele, and the susceptibility to the
isease was found [ACE DD OR = 1.86 (95% CI 1.26–2.76), p = 0.002]. After adjustment for age, gender, traditional cardiovascular risk
actors, and CAD, PAD and CVD, ACE DD genotype still affected the susceptibility to AAA [OR = 2.13 (95% CI 1.06–4.28), p = 0.03], and
he contemporary presence of ACE DD genotype and TGFBR1 6A allele, increased the predisposition to the disease [OR = 5.09 (95% CI
.44–18.02), p = 0.01]. This study, which demonstrates an interaction between ACE and TGFBR1 genes in predisposing to AAA, may provide
urther information on the mechanisms contributing to AAA susceptibility, and offer a topic for future larger studies.
2008 Elsevier Ireland Ltd. All rights reserved.
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. Introduction
Abdominal aortic aneurysm (AAA), a chronic degen-
rative condition, is associated with atherosclerosis and
haracterized by dilation of the aortic wall and segmental
eakening.
∗ Corresponding author at: Department of Medical and Surgical Critical
are, Thrombosis Centre, University of Florence, Viale Morgagni 85, 50134
lorence, Italy. Tel.: +39 0557949420; fax: +39 0557949418.
E-mail address: cinziafatini@hotmail.com (C. Fatini).
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The pathogenesis of this complex disorder is the result
f the interaction between multiple genes and multiple envi-
onmental factors, and remains not yet completely defined.
ctually, there is increasing information on the relevance of
nvestigating polymorphisms in candidate genes for AAA,
n order to evaluate their influence on susceptibility to this
ondition.We previously demonstrated a role for the angiotensin
onverting enzyme (ACE) I/D, but not angiotensin II type
receptor (AT1R) 1166A>C polymorphism, as predispos-
ng factor to AAA [1], probably related to the increased
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xpression of ACE in human aneurismal aorta. This obser-
ation has been strengthened by experimental data, which
emonstrated that angiotensin II infusion produces large
AA in apo-E deficient mice [2], and, in a Marfan mouse
odel, angiotensin II type 1 receptor blockers treatment pre-
ented the aortic aneurysm development [3]. Furthermore,
linical studies demonstrated that in patients with established
AA, ACE-inhibitors augment systemic collagen synthe-
is and reduce stiffness of the aortic wall [4], and, most
mportantly, are able to reduce the risk of ruptured AAA [5].
ngiotensin II may affect the vascular tissue remodelling by
ctivation of growth factors and inflammation, through the
ocal induction of TGF- [6]. Gray et al. [7] showed that
ngiotensin II stimulates cardiac myocytes to release TGF-
1, thus contributing to cardiac myocyte hypertrophy, and in
mouse model of Marfan syndrome increased TGF- sig-
alling was demonstrated to contribute to the formation of
ortic aneurysm [3]. Really, treatment with TGF- antago-
ists, such as TGF- neutralizing antibody, or angiotensin
I type 1 receptor (AT1) blockers, was shown to prevent the
ilatation of aorta [3].
Dysregulated TGF- signalling results from mutations
n TGFBR1, and TGFBR2 genes codifying for the serine-
hreonine protein kinase receptors of TGF- (TGFR type I
nd type II), so leading to an altered phenotype of TGF-,
nd in turn resulting in degenerative changes in the vessel
all, which lead to aneurysm formation [8]. A polymor-
hism (TGFBR19A6A), which consists of 3 alanines deletion
ithin a polyalanine sequence repeated 6 or 9 times, at the
′
-end of exon 1 in the TGFBR1 gene has been identified
9]. The 6A rare allele encodes a transmembrane receptor
hat lacked three alanine residues. The 6A and 9A alle-
es differ in their signal sequences and not their mature
eceptors. The altered TGF- signalling due to 6A allele
ould influence the pathways that regulate TGF- signalling
9].
At the best of our knowledge, no data are available con-
erning the role of the TGFBR1 9A6A polymorphism as
redisposing factor to AAA. Angiotensin II high levels,
elated to the presence of ACE D allele, may affect vascu-
ar tissue remodelling, by activating growth factors, such as
GF-. Therefore, we carried out the present study, in the
ame group of AAA patients previously analysed for the ACE
nd AT1R polymorphisms [1], in order to investigate the role
f TGFBR1 9A6A polymorphism as predisposing factor to
AA per se, and in the presence of ACE DD and AT1R 1166
C genotypes.
. Methods
.1. Study populationThe current study group, including 201 out of 250 con-
ecutive patients with AAA referred to the Unit of Vascular
urgery of the University of Florence, has been previously
p
N
ssis 202 (2009) 205–210
nalysed for the ACE I/D and AT1R 1166A>C polymor-
hisms [1].
AAA was defined as a focal dilation of the abdominal
orta at least 50% larger than expected normal diameter,
ccording to the current report standard [10]. Exclusion crite-
ia were the presence of familial (18%) and/or inflammatory
2%) aneurysms. Familial AAA was considered in patients
ith one or more first-degree family members with AAA,
hereas inflammatory AAA was diagnosed on the basis of
perative appearance (presence of extensive perianeurysmal
nd retroperitoneal fibrosis, and dense adhesion to adjacent
bdominal organs).
A group of 252 healthy subjects recruited from partners or
riends of patients, and comparable for age and gender was
sed as control group. All controls had no AAA and a detailed
nterview addressing personal and family history was per-
ormed within a physical examination by expert physicians,
n order to identify subjects with no symptoms of vascular
isease and to exclude who was suspected of having any
ind of vascular disease. All subjects gave informed consent;
he study was approved by the local ethics committee and
omplies with the Declaration of Helsinki.
All subjects underwent duplex scanning examination
sing an Acuson Sequoia Color Duplex System (Mountain
iew, CA, USA) with a multi-frequency convex probe, rang-
ng from 5 to 2 MHz. Ultrasound scanning examination was
hen confirmed in patients by angio-CT scan. Digital sub-
raction angiography was performed only in patients with
oncomitant peripheral arterial disease (PAD) and in patients
andidate to endovascular treatment of AAA when angio-
T study was not satisfactory to evaluate the feasibility of
ndovascular treatment.
Aortic diameter was measured below the origin of
enal arteries in both groups. The subjects were classi-
ed as having hypertension according to the guidelines
f European Society of Hypertension/European Soci-
ty of Cardiology (systolic blood pressure > 140 mmHg,
nd diastolic blood pressure > 90 mmHg for ≥2 repeated
easurements) [11], or if they reported taking antihy-
ertensive medications, as verified by the physicians.
yslipidemia was defined following the criteria of the ATP
II Expert Panel of the US National Cholesterol Educa-
ion Program, as having fasting serum total cholesterol
oncentrations > 220 mg/dL, LDL-C > 140 mg/dL, triglyc-
ride > 150 mg/dL, HDL-C < 40 mg/dL [12], or if they
eported taking anti-dyslipidemic medications, as verified by
he physicians. Smoking status was determined at the time
f blood collection: smoking history included past smoking
≥10 years) and current smoking.
In order to assess the presence of coronary artery disease
CAD) patients were evaluated according to the ACC/AHA
uidelines [13]. Severe carotid stenosis, confirmed by com-
uted tomography angiography, was defined according to the
ASCET criteria [14].
PAD was documented as present if ankle/brachail pres-
ure index was less than 0.9. On the basis of these criteria,
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0 (29.8%) patients had clinical evidence of CAD, 18 (8.9%)
ad cerebrovascular disease (CVD) and 32 (15.9%) PAD.
neurysmal size was measured by means of computed
omography.
.2. Detection of ACE I/D, AT1R 1166A>C and
GFBR1 6A9A polymorphisms
Genomic DNA was extracted from peripheral blood
eukocytes using a QIAmp Blood Kit (QIAGEN, Hilden,
ermany).
The TGFBR1 6A9A polymorphism was amplified by PCR
mplification using TAQ DNA polymerase (Amersham) and
he following primer pair (5′-gac cat gga ggc ggc ggt c-3′
nd 5′-gtc gcc ccc ggg agc ag-3′; primers modified from
asche et al. [9], at an annealing temperature of 62 ◦C).
CR fragments were loaded on a 4% agarose gel and sub-
itted to electrophoresis for 1 h to separate the different
lleles.
The ACE I/D and AT1R 1166A>C polymorphisms were
enotyped as already described [1].
.3. Statistical analysis
Statistical analysis was performed by using Statistical
ackage for Social Sciences (SPSS Inc., Chicago, IL, USA)
oftware for Windows (Version 11.5, Copyright ©SPSS Inc.).
ata are expressed as mean ± S.D. or median and range.
he non-parametric Mann–Whitney test was used to test
or comparison between single groups. Kruskall–Wallis test
sed for comparisons among different groups. The χ2-test
as used to test for deviation of genotype distribution from
ardy–Weinberg equilibrium.
The number of subjects studied was sufficient to detect,
ith a statistical power of 80% (β = 0.8) and significance
alue of 0.05 (α), absolute differences in ACE allele frequen-
ies between patients and controls.
In our previous study [1] we performed the statistical
nalysis under a recessive genetic model of inheritance.
n the present study, due to the lack of subjects (both
atients and controls) homozygous for the TGFBR1 6A
llele, the association between TGFBR1 polymorphism and
AA was assessed by using a logistic regression analysis
v
c
a
(
able 1
emographic characteristics and traditional cardiovascular risk factors of the study
ariable Patients (n = 201)
ge (years)a 71.5 ± 6.9
ales, n (%) 175 (87)
emales, n (%) 26 (13)
ypertension, n (%) 145 (72.1)
yslipidemia, n (%) 82 (40.8)
moking habit, n (%) 140 (69.6)
bdominal aortic diameter (cm)a 6.1 ± 1.3
< 0.05, significant value.
a Mean ± S.D.sis 202 (2009) 205–210 207
nder a dominant genetic model, which compares individ-
als with one or more polymorphic alleles with a baseline
roup with no polymorphic alleles (e.g. TGFBR1 9A6A vs.
A9A).
All variables that resulted with a p-value < 0.05 in the uni-
ariate analysis (hypertension, dyslipidemia, and smoking
abit) were introduced into a multivariable model. Variables
s age and gender were also included into the multivariable
odel. Odds ratio (OR) with 95% confidence interval was
etermined.
. Results
The demographic and clinical characteristics of the study
opulation are reported in Table 1. A significant difference
etween patients and controls has been observed in relation
o cardiovascular risk factors, and aortic diameter. The geno-
ype distribution and allele frequency of the ACE I/D, AT1R
166A>C andTGFBR1 6A9A polymorphisms were in agree-
ent with those predicted by Hardy–Weinberg equilibrium.
significant difference in both genotype distribution and
llele frequency between AAA patients and controls was
bserved for ACE I/D, but not for the other two polymor-
hisms analysed (Table 2).
At both univariate and multivariate analysis, no signif-
cant association between the TGFBR1 polymorphism and
he susceptibility to AAA was found (Tables 3 and 4). As
reviously observed [1], at both univariate and multivariate
nalysis after adjustment for confounding variables, for tra-
itional cardiovascular risk factors (hypertension, smoking
abit, dyslipidemia), and the presence of other atheroscle-
otic disease (i.e. CAD, PAD, and CVD), a significant
ssociation between ACE DD genotype and the predispo-
ition to the disease was found (OR 1.86, p = 0.002 and
R 2.13, p = 0.03, respectively) (Tables 3 and 4). Never-
heless, subjects homozygous for the ACE D allele and
ontemporary carrying the TGFBR1 6A allele, showed a
ignificant increased predisposition to AAA at both uni-
ariate and multivariate analysis (Tables 3 and 4). The
ontemporary presence of AT1R 1166C and TGFBR1 6A
lleles did not influence the predisposition to the disease
Table 4).
population
Controls (n = 252) p-Value
70.6 ± 8.6 0.1
216 (85.7) 0.9
36 (14.3) 0.7
21 (8.3) <0.0001
32 (12.7) <0 .0001
45 (17.9) <0 .0001
1.9 ± 1.2 <0 .0001
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Table 2
Genotype distribution and allele frequencies of ACE, AT1R and TGFBR1 polymorphisms
Genotype Allele Patients (n = 201), n (%) Controls (n = 252), n (%) p-Value
ACE II 34 (16.9) 59 (23.4)
ACE ID 82 (40.8) 122 (48.4)
ACE DD 85 (42.3) 71 (28.2) 0.006
ACE D 0.63 0.52 0.002
AT1R AA 96 (47.8) 121 (48.0)
AT1R AC 86 (42.8) 108 (42.9)
AT1R CC 19 (9.5) 23 (9.1) 0.9
AT1R C 0.31 0.30 0.9
TGFBR1 9A/9A 170 (84.6) 209 (82.9)
TGFBR1 9A/6A 31 (15.4) 43 (17.1)
TGFBR1 6A/6A 0 (0)
TGFBR1 6A 0.08
p < 0.05, significant value.
Table 3
Univariate analysis for ACE, AT1R and TGFBR1 polymorphisms
OR 95% CI p-Value
Age 1.02 0.99–1.04 0.2
Gender 0.89 0.52–1.53 0.67
Smoking habit 10.55 6.79–16.40 <0.0001
Hypertension 28.48 16.55–49.01 <0.0001
Dyslipidemia 4.73 2.97–7.54 <0.0001
ACE DD vs. ID + II 1.86 1.26–2.76 0.002
AT1R CC vs. AC + AA 1.04 0.55–1.96 0.9
TGFBR1 6Aa vs. 9Ab 0.89 0.53–1.47 0.6
Combined genotypes
ACE DD × 6A vs. (ID + II) + 9A 2.38 1.07–5.28 0.03
AT1R CC × 6A vs. (AC + AA) + 9A 1.25 0.17–8.99 0.82
ID + II = subjects with ACE ID and II genotypes; AC + AA = subjects with
AT1R AC and AA genotypes. p < 0.05, significant value.
e
(
t
d
T
M
V
A
G
S
H
D
A
T
C
p
P
4
g
g
f
n
p
p
w
p
r
f
t
related with a dose dependent effect [15] to the presence of the
ACE D allele, might lead to the remodelling of vascular tis-
sue by activating growth factors, such as TGF- transcription
and synthesis.
Table 5
Aortic diameters according to ACE, AT1R and TGFBR1 polymorphismsa 6A = 6A/9A (lack of 6A/6A homozygotes).
b 9A = 9A/9A homozygotes.
As far as aortic diameter is considered, we found no differ-
nce among genotypes for the three polymorphisms analysed
Table 5). The contemporary presence of homozygosity for
he ACE D and TGFBR1 6A allele did not affect the aortic
iameter (Table 5).
able 4
ultivariate analysis for ACE, AT1R and TGFBR1 polymorphisms
ariable ORa 95% CI p-Value
ge 1.05 0.98–2.29 0.06
ender 1.21 0.54–2.72 0.6
moking habit 15.45 8.03–29.71 <0.0001
ypertension 42.66 20.80–87.51 <0.0001
yslipidemia 1.18 0.58–2.40 0.6
CE DD 2.13 1.06–4.28 0.03
GFBR1 6A 0.76 0.32–1.82 0.5
ombined genotypes
ACE DD ×TGFBR1 6A 5.09 1.44–18.02 0.01
< 0.05, significant value.
a Adjusted for age, gender, traditional cardiovascular risk factors, CAD,
AD, CVD, and for the ACE and TGFBR1 polymorphisms.
G
A
A
T
V0 (0) –
0.08 0.6
. Discussion
In this study we contributed to better define the role of the
enetic makeup in the pathogenesis of a complex and poly-
enic disorder, such as AAA. Our study documents a role
or TGFBR1 gene in modulating the predisposition to AAA
ot per se, but only when increased angiotensin II levels are
resent. Really, the 6A allele of the TGFBR1 9A6A polymor-
hism influences the susceptibility to AAA in patients who
ere also homozygous for the ACE D allele, but not in the
resence of the AT1R 1166C allele.
We previously demonstrated that ACE DD genotype rep-
esented a marker of increased susceptibility to AAA [1] apart
rom traditional cardiovascular risk factors, and hypothesized
hat increased angiotensin II levels, which are known to beenotype Patients (n = 201)
(mean ± S.D.)
p-Value
CE
DD 6.0 ± 1.2
ID 5.8 ± 1.1 0.09a
II 6.3 ± 1.4
T1R
CC 5.6 ± 0.8
AC 6.0 ± 1.3 0.3a
AA 6.0 ± 1.2
GFBR1
6A/6A –
6A/9A 6.3 ± 1.2 0.06b
9A/9A 5.9 ± 1.2
ACE DD × TGFBR1 6A
combined genotype
6.25 ± 1.28 0.29b
alues are expressed in cm. p < 0.05, significant value.
a Non-parametric test: p for trend Kruskall–Wallis test.
b Non-parametric test: Mann–Whitney test.
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TGF- represents an important molecular determinant of
all strengthening during vascular development [16], and
ediates responses of vessels submitted to injury, by pro-
oting intimal tissue accumulation [17]. AAA shows an
nexorable tendency to expand under radial hemodynamic
tress [18] with clinically relevant consequences because of
essel rupture. In experimental AAAs animal models, and
n an explant model, by using human atherosclerotic incu-
ated AAA fragments, it has been demonstrated that active
GF-over-expression is able to promote stability of expand-
ng AAA already injured by inflammation and proteolysis
19]. Conversely, data from experimental studies showed
hat the inhibition of TGF- signalling favours the devel-
pment of lesions with increased inflammatory component
nd decreased collagen content [20], so shifting towards a
henotype depleted in extracellular matrix. TGF- circulat-
ng concentration is dependent on TGFBR1 gene, which has
een recently investigated as a candidate gene in the spo-
adic AAA onset [21]. TGF- induces extracellular matrix
ECM) formation by binding to its two receptors TGFR
ype I and II [22], and mutations in genes encoding for TGF-
eceptors may lead to ECM degradation, activation of matrix
etalloproteinases, apoptosis and inflammation [8].
Mutations in TGFBR2 gene are present in families with
arfan’s syndrome [23] or familial thoracic aortic aneurysm
nd dissection [24], but no data are present concerning the
ole of TGFBR1 gene in both familial or sporadic AAA. The
GFBR1 6A/9A polymorphism is located at the amino ter-
inus of TGFBR1 gene, near the cleavage signal sequence
f the protein. The lack of the three alanines in the TGFBR1
A allele might induce either the transcriptional inactivation
r the alteration of pathways that regulate TGF- signalling
25], so influencing the role of TGF- signalling in triggering
he responses to aneurysmal wall injury in AAA.
Angiotensin II, the final effector of the renin angiotensin
ystem, through the activation of AT1 receptor, increases
GF- mRNA levels [26] and up-regulates TGFBR2
xpression [6]. Experimental data demonstrated that an
ver-expression of active TGF- pathway has a role in re-
stablishing the aortic wall ability to resist wall stress due
o inflammation and proteolysis [19]. Inhibition of TGF-
ignalling might accelerate the development of aortic wall
esions because of increasing inflammatory components and
ecreasing the collagen content, so lacking of its major pro-
ective role. Emerging evidence links the renin angiotensin
ystem to the development of aortic aneurysm, and a role
or increased angiotensin II levels, related to ACE D allele, in
nfluencing the remodelling of vascular tissue, thus determin-
ng AAA formation has been suggested [1]. Recently results
rom a meta-analysis of 26 case-control studies looking at 78
ifferent single nucleotide polymorphisms, and performed
n order to analyse candidate genes for AAA, provide evi-
ence for a role of ACE gene in affecting predisposition to
AA [27]. Moreover, a large study (n = 1226 AAA patients
nd 1723 controls) investigating 3 geographically distinct
ohorts, confirmed a role for ACE gene in modulating the
i
a
o
asis 202 (2009) 205–210 209
usceptibility to the disease, and demonstrated that the AT1R
166A>C polymorphism represented a risk factor for AAA.
28]. The present study does not provide evidence of a role
or this polymorphisms in influencing the susceptibility to the
isease. This conflicting finding may be due to the different
enetic background of the examined populations, and to the
ifferent sample size.
Interestingly, experimental studies provided evidence of
benefit of ACE inhibitors treatment in preventing aor-
ic expansion and rupture [29], and clinically relevant data
rom a large population study (n = 15,326) showed that ACE-
nhibitors therapy was associated with a reduced risk of aortic
upture in patients who had AAA [5]. Moreover, in patients
ith established AAA, ACE inhibitors therapy is able to aug-
ent collagen synthesis and reduce stiffness of the aortic wall
4], and to attenuate angiotensin II-induced atherosclerosis
nd vascular inflammation [30].
Therefore, based on the above-mentioned observations,
e could speculate that the decrease in function of TGFR1,
elated to TGFBR1 6A allele, may lead to the lack of TGF-
signalling protective role, and, in the presence of high
ngiotensin II levels, predispose to AAA.
Our findings failed to demonstrate the influence of
GFBR1 gene on the aortic diameter, as any difference in
AA dilation among TGFBR1 genotypes has been observed.
he same datum, concerning the ACE and AT1R genes, has
een provided in our previous report [1], so strengthening the
bservation of a genetic role in influencing the susceptibility,
ut not the severity of the disease.
This study has some limitations. First, ACE and TGFBR1
olymorphisms did not justify more than a part of genetic
usceptibility in this complex disorder, suggesting that other
andidate genes are certainly implicated in AAA determina-
ion. Nevertheless, we observed an interaction between ACE
nd TGFBR1 genes in influencing the susceptibility to AAA,
hus offering a better understanding of the hereditary contri-
ution to the disease. Second, we did not provide information
f the ACE phenotype. Genetic case-control association stud-
es look for correlations between phenotype and genotype
nd represent the most common studies used to evaluate
he genetic basis of disease predisposition. Really, some
olymorphisms, such as the ACE I/D polymorphism, have
unctionally significant effects on the gene product, and data
rom experimental studies reported both a functional role for
he ACE I/D polymorphism in modulating angiotensin II lev-
ls [31], and an increased mRNA expression in white blood
ells from subjects carrying the ACE D allele in compari-
on to subjects carrying the I allele [32]. Third, the control
roup consists of clinically healthy subjects with no evidence
f atherosclerotic disease, whereas the optimal comparable
roup would be represented by atherosclerotic subjects with
o AAA. Finally, another limitation of the study is the lack of
nformation concerning both the BMI and lifestyle, such as
lcohol consumption, which are relevant in affecting the risk
f cardiovascular disease, and inflammatory markers, which
re involved in the atherosclerotic process.
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In conclusion, the present study, which shows a role of
CE and TGFBR1 genes in predisposing to AAA apart
rom traditional cardiovascular risk factors, may permit to
ypothesize a possible mechanism responsible for AAA
usceptibility, and may contribute to characterize a genetic
attern of population susceptibility, by using the putative
unctional polymorphisms in candidate genes. Finally, it
ight offer an interesting topic for future studies performed
n both larger, as well as different ethnic populations.
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